Vesting
-
)”.Scholar Rock Files New Employee Inducement Grants Under Nasdaq Rule 5635(c)(4)
words.Scholar Rock (NASDAQ: SRRK) granted inducement equity awards to two new executives—4,457 stock options and 3,343 restricted stock units—under its 2022 Inducement Equity Plan, subject to Nasdaq Listing Rule 5635(c)(4). The options have a $45.25 exercise price and vest 25% after one year, then quarterly; the RSUs vest annually over four years. The awards dilute shareholders by ~0.4% of float and will increase compensation expense. The move aims to attract talent to advance the apitegromab program for SMA and other rare neuromuscular disorders, amid strong biotech market momentum.
-
Signature Resources Announces Option Grants to Directors, Management, and Advisors
On October 17, 2025, Signature Resources (OTCQB: SGGTF; TSXV: SGU) granted 2,400,000 incentive stock options to its board, management, and advisors. The options have an exercise price of $0.055, aligning with the concurrent financing price, and expire in five years. Vesting is 25% immediately, followed by 25% annually until the third anniversary. These options serve as the sole compensation for non-executive directors and are subject to the company’s Option Plan and regulatory approvals.
-
Neuronetics Announces Inducement Grant per Nasdaq Listing Rule 5635(c)(4)
Neuronetics, Inc. has granted inducement awards to a new non-executive employee. The compensation includes Performance Restricted Stock Units (PRSUs), vesting upon achieving cash flow breakeven targets, and Restricted Stock Units (RSUs), vesting over three years. These awards are part of the company’s 2020 Inducement Incentive Plan, and are subject to continued employment. Neuronetics focuses on treating neurohealth disorders with its NeuroStar Advanced Therapy, a non-invasive treatment for MDD and other conditions.
